London, UK, 23 January 2007: BioProgress plc (‘BioProgress’ or the ‘Company’) (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, announces that it has successfully achieved indicative stability for its DBP117 Migraine treatment product using its propriety Soluleaves™ technology. It has also developed the patented nicotine DBP121 thin strip product, which will shortly be entering stability for the smoking cessation market. Both products are designed to undergo rapid development and commercialisation.
